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ABSTRACT. Regulated on activation, normal T-cell expressed and 
secreted (RANTES) and stromal cell-derived factor 1 (SDF-1) are 
members of the CC- and CXC-chemokine families, respectively. 
Both genes have been postulated to be involved in the pathogenesis of 
systemic lupus erythematosus (SLE). We analyzed position 28 of the 
RANTES gene promoter region, as well as the SNP observed in the 3' 
UTR of the SDF-1 gene at position 801, in 130 patients presenting SLE 
at the Malaya University Medical Centre. Screening of 130 healthy 
volunteer controls using RFLP was also performed. RANTES-28 
polymorphism analysis showed no significant (P = 0.3520) relationship, 
even though homozygous C/C was more frequent in SLE patients (OR 
= 1.4183) and heterozygous C/G was more frequent in healthy controls 
(OR = 0.7051). There were no significant (P = 0.2650) associations 
between A/A (OR = 0.783), G/G (OR = 1.5914) and G/A (OR = 0.8289) 
genotypes in the SDF-1 gene polymorphism with SLE. We conclude 
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that there is no significant association of RANTES-28 and SDF-1 gene 
polymorphisms and occurrence of SLE in Malaysia.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that manifests 
as severe inflammation of multiple organs. The usual affected organs include the brain, heart, 
skin, joints, kidneys, lungs, and blood vessels (Katsiari and Tsokos, 2006). SLE is character-
ized by pathogenic autoantibodies in the systemic circulation, which damage the organs upon 
deposition of immune complexes. Physicians often have difficulties diagnosing SLE accu-
rately at initial stages due to clinical symptoms and complications that are similar to other au-
toimmune diseases, e.g., rheumatic arthritis and multiple sclerosis. Furthermore, the severity 
of SLE is highly variable, ranging from being mild to deadly. The symptoms in SLE patients 
include fever, multiple joints pain, skin rashes, malaise, extreme fatigue, and kidney problems. 
The butterfly-shaped rash that presents over the nose-bridge is a distinctive feature of SLE. 
Unfortunately, medications only relieve symptoms, reduce inflammation and slow down the 
disease’s progression; there is no cure for this disease (Wallace and Hann, 2002).
Broadly, the exact cause of SLE remains unknown, despite extensive studies carried 
out all over the world to investigate the etiology of this disease. Researchers have postulated 
that initiation of SLE is possibly due to interaction of three major factors, these being genetic, 
endocrine-metabolic, and environmental. It is hard to draw a clear cut conclusion on how 
these factors affect the onset of SLE due to the poorly understood pathogenesis of SLE and 
the mechanisms involved in its initiation. There is no single gene reported to be responsible for 
the disease. It is suggested that a complex interaction of multiple genes may be involved, trig-
gering the onset of SLE. SLE is a gender-biased disease that affects mostly females (approxi-
mately nine females to one male), more so during their child-bearing age. This is believed to 
occur due to hormonal changes in women during puberty (Danchenko et al., 2006). Also, the 
prevalence rate of SLE is at least 2- to 4-folds higher in Afro-Americans, Afro-Caribbeans, 
and Asians, when compared to Caucasians (Hochberg, 1985). In Malaysia, the prevalence rate 
of SLE is more common in Chinese, than in Malay and Indian ethnicities (57, 33, and 14 per 
100,000 persons, respectively; Wang et al., 1997). The mean mortality rate for patients with 
SLE in Malaysia is 20.2% (Yeap et al., 2001).
Regulated on activation normal T-cell expressed and secreted (RANTES) is a member 
of the CC-chemokine family that selectively attracts T-cells, monocytes, eosinophils, and ba-
sophils (Ortiz et al., 1996). It has been extensively studied in allergic and infectious diseases 
(Nickel et al., 2000). RANTES is expressed in airway epithelial cells, platelets, fibroblasts, 
activated T-lymphocytes, renal epithelial, and mesangial cells (Nickel et al., 2000). The T-
lymphocytes are attracted to the site of inflammation after early and transient RANTES acti-
vation by cells in injured tissues (Ortiz et al., 1996). T-lymphocytes will then encounter the 
antigen, fully differentiate and produce large amounts of RANTES, through which the inflam-
matory response is amplified (Ortiz et al., 1996). The RANTES gene is located on chromosome 
17q11.2-q12, spanning 8.8 kb (An et al., 2002). It consists of three exons and two introns (An 
et al., 2002). There are seven single nucleotide polymorphisms (SNPs) in the RANTES gene; 
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four are in the promoter regions, two in the first intron, and one in the 3' untranslated region 
(UTR). One of the SNPs that is present at position 28 in the promoter region of the RANTES 
gene, has a cytosine (C) to guanine (G) variation. This polymorphism is proposed to elevate 
the promoter activity of RANTES, increasing the expression of RANTES in humans (Ye et 
al., 2005a).
Stromal cell-derived factor 1 (SDF-1) is a member of the CXC-chemokine family 
that is found on chromosome 4 (Bleul et al., 1996). It is also known as CXCL12, which was 
originally identified as a growth factor for murine pre-B cells (Ye et al., 2005b). SDF-1 plays 
an important role in the regulation of migration, proliferation, differentiation of hematopoetic 
cells, as well as being involved in the homeostatic and inflammatory traffic of leukocytes 
(Lima et al., 2007). The receptor for SDF-1 is CXCR4, and interaction between SDF-1 and 
its receptor plays a vital role in CD4+ T-cell accumulation in the synovium in patients with 
rheumatoid arthritis. SDF-1 is also known to inhibit activation-induced apoptosis of T-cells 
(Ye et al., 2005b). This condition can lead to production of pathogenic autoantibodies (Lima 
et al., 2007). An SNP was found in the 3' UTR of the SDF-1 gene at position 801 (Lima et al., 
2007). The polymorphism is characterized by a G to adenine (A) variation that can increase 
the transcriptional activity of the SDF-1 gene, resulting in production of larger quantities of 
SDF-1 proteins (Ye et al., 2005b). Here, we examined the SNPs in both the promoter region 
of RANTES and 3' UTR of the SDF-1 genes. We also looked at possible association of these 
SNPs with SLE in the Malaysian population.
MATERIAL AND METHODS
Sample collection and genomic DNA extraction
Two hundred and sixty blood samples were collected with informed consent from pa-
tients attended at the University Malaya Medical Centre (UMMC), Kuala Lumpur. These con-
sisted of 130 SLE patients and 130 healthy volunteer controls. In general, the patients ranged 
in age from 16 to 50 years and their clinical manifestations were renal disorder with protein-
uria (>0.5 g/day), malar rash, arthritis, and photosensitivity with production of anti-dsDNA at 
>200 IU/mL. Blood samples were collected in EDTA tubes and genomic DNA was extracted 
via a conventional phenol-chloroform extraction method. Both the quality and quantity of the 
extracted DNA were then determined using spectrophotometry.
Amplification of the RANTES gene
Amplification of the promoter region of the RANTES gene was carried out via PCR with 
primers, as described in a previous study (Ye et al., 2005a). The 20-µL amplification reaction 
contained 10 ng genomic DNA, 2 µL 10X Taq buffer with KCl, 1.5 mM MgCl2, 0.075 mM dNTP 
mixture, 0.375 µM of each forward and reverse primers, and 0.75 U Taq DNA polymerase. The 
primer sequences used for the analysis of RANTES-28 polymorphisms in this study were as 
follows: 5'-ACAGAGACTCGAATTTCCGGA-3' and 5'-CCACGTGCTGTCTTGATCCTC-3'. 
PCR amplification was carried out at 95°C, for 5 min in the initial denaturation, followed by 35 
cycles of 94°C for 40 s, 65°C for 40 s, 72°C for 40 s, and a final extension at 72°C for 10 min. 
The PCR product (173 bp) was then subjected to overnight digestion with 3 U MnlI at 37°C. 
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The digested products were then electrophoresed on 3% (w/v) ethidium bromide-stained aga-
rose gels and observed under ultra-violet (UV) light. C and G alleles were indicated by the 
presence of 126 and 146 bp fragments, respectively (Figure 1).
Figure 1. Amplified and digested products of the RANTES-28 polymorphisms on an agarose gel. Lane 1 = 50-
bp DNA ladder; lane 2 = undigested PCR product; lane 3 = digested PCR product (homozygous C/C); lane 4 = 
digested PCR product (heterozygous C/G); lane 5 = DNA blank.
Amplification of the SDF-1 gene
Amplification of the SDF-1 3' UTR was carried out using primers described by Lima 
et al. (2007). The 20-µL amplification reaction contained 10 ng genomic DNA, 2 µL 10X 
Taq buffer with 500 mM KCl, 1.5 mM MgCl2, 0.075 mM dNTP mixture, 0.375 µM each for 
forward and reverse primers, and 0.75 U Taq DNA polymerase. The primer sequences were: 
5'-AGTCAACCTGGGCAAAGCC-3' and 5'-AGCTTTGGTCCTGAGAGTCC-3'. The PCR 
cycling program was set at 95°C for initial denaturation, followed by 35 cycles of 95°C for 40 
s, 57°C for 40 s, 72°C for 40 s, and a final extension at 72°C for 10 min. The PCR product (301 
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bp) was then digested overnight with 2 U MspI at 37°C. Following that, the digested products 
were electrophoresed on 2% (w/v) agarose gels. The A allele was indicated by an undigested 
fragment (301 bp), whereas, cleaved fragments (99 and 202 bp) indicated presence of the G 
allele (Figure 2).
The chi-square test was carried out for statistical analysis; allele frequencies were also 
estimated by the gene-counting method. The frequencies of the alleles and genotypes were 
compared between patient and control groups by the chi-square test, when appropriate. The 
odds ratio (OR) and 95% confidence intervals (95%CI) were also estimated. The chi-square 
test was used to examine the deviation of genotype distribution from the Hardy-Weinberg 
equilibrium.
Figure 2. Amplified and digested products of the SDF-1 gene polymorphisms on agarose gel. Lane 1 = 50-bp DNA 
ladder; lane 2 = undigested PCR product; lane 3 = digested PCR product (homozygous A/A); lane 4 = digested 
PCR product (heterozygous G/A); lane 5 = digested PCR product (homozygous G/G); lane 6 = DNA blank.
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RESULTS
Table 1 shows the allelic frequencies of RANTES-28 polymorphisms; both the C and 
G alleles were observed. The frequency of C alleles was higher in both SLE patients and 
healthy controls. However, there was no significant difference in the frequency of C and G 
alleles in the comparison between SLE patients and healthy controls (χ2 = 0.809, P = 0.3684. 
Neither the C (OR = 1.3853, 95%CI = 0.6791 to 2.8257) nor G alleles (OR = 0.7219, 95%CI 
= 0.3539 to 1.4725) were significantly associated with this disease. The homozygous C/C 
genotype was more common than the heterozygous C/G genotype. The frequency of the 
heterozygous C/G genotype was relatively low in both SLE patients and healthy controls. 
Surprisingly, no homozygous G/G genotypes were observed in the SLE patients or healthy 
controls. The distribution of the different genotypes was similar in both the cohorts of SLE 
patients and healthy controls. There was no significant association of homozygous C/C and 
heterozygous C/G genotypes with either SLE patients or healthy controls (χ2 = 0.868, P = 
0.3520). Furthermore, there was no significant association between C/C homozygotes (OR = 
1.4183, 95%CI = 0.6782 to 2.9661) and C/G homozygotes (OR = 0.7051, 95%CI = 0.3372 
to 1.4764) with SLE disease.
RANTES-28 Frequency χ2 value (P value) OR value (95%CI)
 SLE patients (N = 130) Healthy controls (N = 130)
Genotype
   C/C 116 111 0.868 (0.3520) 1.4183 (0.6782-2.9661)
   C/G   14   19  0.7051 (0.3372-1.4764)
   G/G     0     0  -
Allele    
   C 246 241 0.809 (0.3684) 1.3853 (0.6791-2.8257)
   G   14   19  0.7219 (0.3539-1.4725)
Table 1. Allelic frequency (N), χ2 (P) value, odds ratio (OR), and 95% confidence interval (95%CI) of RANTES-28 
polymorphisms in Malaysian systemic lupus erythematosus (SLE) patients and healthy controls.
In the study of SDF-1 3' UTR polymorphisms (Table 2), the frequency of the A allele 
was higher in healthy controls. On the other hand, the G allele was more commonly observed 
in Malaysian SLE patients. However, there were no significant differences in the frequencies 
of A and G alleles between SLE patients and healthy controls (χ2 = 1.973, P = 0.1601. The A 
(OR = 0.7811, 95%CI = 0.5533 to 1.1027) and G alleles (OR = 1.2802, 95%CI = 0.9068 to 
1.8073) were not significantly associated with SLE disease in the Malaysian population. The 
heterozygous G/A genotype was most commonly observed in both Malaysian SLE patients 
and healthy controls. On the other hand, the frequency of the homozygous A/A genotype was 
higher in healthy controls, while the homozygous G/G genotype was frequently scored in SLE 
patients. However, the distribution of each of the genotype was similar between SLE patients 
and healthy controls. There was no significant difference in the distribution of the three geno-
types between SLE patients and healthy controls (χ2 = 2.660, P = 0.2650). Moreover, there 
was also no significant association between the homozygous A/A genotype (OR = 0.7830, 
95%CI = 0.4235 to 1.4478), the heterozygous G/A genotype (OR = 0.8289, 95%CI = 0.5075 
to 1.3537) and the homozygous G/G genotype (OR = 1.5914, 95%CI = 0.8961 to 2.8262) with 
SLE. Statistical analysis also showed that the distribution of genotypes in both the SLE and 
healthy controls were in Hardy-Weinberg equilibrium.
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SDF-1 3' UTR Frequency  χ2 value (P value) OR value (95%CI)
 SLE patients (N = 130) Healthy controls (N = 130)
Genotype
   G/G   37   26 2.660 (0.2650) 1.5914 (0.8961-2.8262)
   G/A   70   76  0.8289 (0.5075-1.3537)
   A/A   23   28  0.7830 (0.4235-1.4478)
Allele
   G 144 128 1.973 (0.1601) 1.2802 (0.9068-1.8073)
   A 116 132  0.7811 (0.5533-1.1027)
Table 2. Allelic frequency (N), χ2 (P) value, odds ratio (OR), and 95% confidence interval (95%CI) of SDF-1 3' 
UTR polymorphisms in Malaysian systemic lupus erythematosus (SLE) patients and healthy controls.
DISCUSSION
The distribution of both allelic and genotypic frequencies of the RANTES-28 poly-
morphisms showed no significant association between the SLE patient and healthy controls in 
the Malaysian population. Only two genotypes, homozygous C/C and heterozygous C/G, were 
found. The homozygous G/G genotype was not observed. A similar observation was made in 
studies carried out on Mexican and Han Chinese populations (Ye et al., 2005a,b). Interest-
ingly, an opposite trend was reported for children of the Han Chinese population (Liao et al., 
2004); children with C/G and G/G genotypes were found to have an increased risk of more 
than double to develop SLE when compared to those with the C/C genotype. Thus, the effect 
of RANTES-28 polymorphisms on the onset of SLE may vary in different age groups.
On the other hand, the RANTES-28 polymorphisms have also been studied in various 
other inflammatory diseases, e.g., asthma, severe acute respiratory syndrome (SARs), atopic 
dermatitis, and juvenile rheumatoid arthritis (JRA). The G allele of the RANTES-28 poly-
morphisms has a significant association with late-onset asthma in the Japanese population 
(Hizawa et al., 2002). This finding was further supported by the increased production level 
of RANTES in vitro in individuals with the G allele (Zhernakova et al., 2006). The G allele 
elevates promoter activity and thus increases the expression of RANTES in T-cells, which can 
lead to cell damage and organ dysfunction. In another study of the association of RANTES-28 
polymorphisms with susceptibility to SARs in Hong Kong and Beijing citizens, individuals 
having G alleles were shown to have a 3-fold increased risk of developing the disease when 
compared to individuals possessing C alleles (Ng et al., 2007). The high level of RANTES 
is believed to predispose individuals with the G allele to SARs. In a study of RANTES-28 
polymorphisms in Japanese patients with atopic dermatitis, the G allele exhibited a strong re-
lationship with disease due to its up-regulating effect on the expression of RANTES (Tanaka 
et al., 2006). Furthermore, G alleles were also shown to decrease the remission duration of 
Taiwan patients, with JRA to 49%, in comparison with patients with the C allele (Yao et al., 
2009). Based on the various studies made of different inflammatory diseases, we suggest that 
up-regulation of the G allele of RANTES-28 plays a role in the onset of SLE by amplifying the 
immune response, which leads to organ damage.
SDF-1 is a protein that acts as pro-inflammatory factor in the immune system; it ac-
tivates and attracts inflammatory cells (such as monocytes and lymphocytes) to the site of in-
flammation (Robak et al., 2007). We did not observe significant association of SDF-1 3' UTR 
polymorphisms with susceptibility to SLE in Malaysian patients. Similar results were also 
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obtained in studies carried out by researchers on other populations (Liao et al., 2004; Ye et al., 
2005b). Both studies demonstrated that the SDF-1 polymorphisms did not associate with SLE. 
In addition, our results are consistent with Warchol’s study, who found no significant differ-
ences in SDF-1 3' UTR variants between Polish SLE patients and healthy controls (Warchol et 
al., 2010). However, they found a significant association of homozygous A and heterozygous 
G/A with SLE patients who had renal manifestations. In another study that investigated as-
sociation of serum levels of SDF-1 rather than association of the SDF-1 gene with SLE, it was 
found that serum levels of SDF-1 were higher in SLE patients than in controls. There was no 
significant difference between active SLE and inactive disease (Robak et al., 2007).
It has been reported that individuals with SDF-1 3' A have higher levels of the SDF-
1 protein due to the up-regulating effect of this allele (Tashiro et al., 1993). Moreover, the A 
allele has also been shown to increase mobilization of CD34+ progenitor cells into peripheral 
blood in humans (Benboubker et al., 2001). As multiple sclerosis is an autoimmune disease 
that involves damage by autoantibodies of the fatty myelin sheaths around the central nervous 
system, SDF-1 3' A has been demonstrated to play a role in the microvascular manifestation in 
multiple sclerosis and thus may be one of the susceptibility factors that lead to disease (Manet-
ti et al., 2009). SDF-1 3' A variants have also been shown to play a role in metastasis of breast 
cancer (Hassan et al., 2008). The expression level of SDF-1 was found to be high in specific 
organs in breast cancer patients bearing the A allele. It serves as a chemoattractant that attracts 
primary breast cancer cells to adhere to the organs and thus promote earlier onset of metastasis 
in breast cancer. In another study carried out in polycythemia vera patients, individuals with 
homozygous A genotypes were found to have an 8-fold higher risk to develop polycythemia 
vera when compared to other genotypes (G/A + G/G) (Gerli et al., 2005). Despite the fact that 
SDF-1 3' A variant is known to contribute to the onset of several diseases, it has been reported 
to convey a protective effect against human immunodeficiency virus (HIV) infection (Winkler 
et al., 1998). This is because SDF-1 and HIV share the same receptor, CXCR4, for entry into 
immune cells. Therefore, high level of SDF-1, induced by the SDF-1 3' A variant, compete 
with HIV for binding to receptors and delay the onset of AIDS in affected patients.
We did not observe any significant association between RANTES-28 and SDF-1 3' 
UTR polymorphisms and SLE in Malaysia. To the best of our knowledge, this is the first study 
relating these SNPs to susceptibility for SLE in Malaysia. Other studies based on complement 
components, interleukins and lymphocyte antigen also failed to demonstrate any significant 
correlations (Puah et al., 2007; Chew et al., 2008; Chua et al., 2009a,b, 2010). Onset of SLE 
might be a result of interaction and involvement of various factors and genes. More studies 
should be conducted to elucidate the mechanisms that are involved in the onset and progres-
sion of SLE disease.
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